Dystonia 16

Dystonia 16 (DYT16), also known as PRKRA-related dystonia or young-onset dystonia-parkinsonism, is a rare inherited movement disorder caused by mutations in the PRKRA gene (also known as DYT16 or PACT). This condition primarily affects the nervous system, specifically the basal ganglia circuits that control voluntary movement. It was first described in Brazilian families and has since been identified in a small number of families worldwide. Dystonia 16 typically presents in childhood or adolescence with progressive dystonia, which involves sustained involuntary muscle contractions causing abnormal postures and repetitive movements. The dystonia often begins in a limb and may generalize over time to affect multiple body regions, including the trunk, limbs, and craniocervical muscles. Many patients also develop parkinsonian features such as bradykinesia (slowness of movement), rigidity, and postural instability. Oromandibular and laryngeal dystonia, leading to speech difficulties (dysarthria), are commonly reported features. Some patients may also exhibit a sardonic smile-like facial expression due to facial dystonia. There is currently no cure for Dystonia 16. Treatment is symptomatic and supportive. Unlike some other forms of dystonia, DYT16 generally shows limited or no response to levodopa therapy. Management may include anticholinergic medications, benzodiazepines, baclofen, and botulinum toxin injections for focal dystonia. Deep brain stimulation (DBS) has been attempted in some cases with variable results. Physical therapy and rehabilitation play an important role in maintaining function and quality of life.

Common questions about Dystonia 16